CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. - Wikidata - awgldk - TriplyDB

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

http://www.wikidata.org/entity/Q37685449

about

Biomaterial-enabled delivery of SDF-1α at the ventral side of breast cancer cells reveals a crosstalk between cell receptors to promote the invasive phenotype.Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.CXCL12-CXCR4 axis in feline mammary carcinoma.Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.Identification of Differentially Expressed Genes between Original Breast Cancer and Xenograft Using Machine Learning Algorithms.miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers.Clinicopathologic Significance of CXCL12 and CXCR4 Expressions in Patients with Colorectal Cancer.The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment

P2860

Q38747909-1865F9CD-99D5-4458-B8D9-96ACB420845F Q47146848-D7616AA0-558A-43F0-99DA-9327AA54CF59 Q49874416-A4740ED5-FD3D-4DE2-AEB5-08B1D7EF1529 Q49894726-E7E18AA7-AE6A-4E7D-8E5E-21C33AD15F61 Q50100841-1151339B-35A5-41DF-BE07-7BDBBEDBB2A4 Q52657721-61D092B3-5E49-4A02-9BC8-2FED54C3726B Q54975654-BB44196F-CC9B-4E28-A150-3517AC492FC6 Q55019874-4B085D0E-ADCF-4B35-8763-734993D70916 Q57492022-A0865F87-323E-4E38-A10C-6CFD9C650562

P2860

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

http://www.wikidata.org/entity/Q37685449

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

@en

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

@nl

type

label

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

@en

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

@nl

prefLabel

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

@en

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

@nl

P1433

Q37685449-5BCD516C-4CB4-403D-BE69-375FB890CAF1

P1476

Q37685449-05EFC411-CEC3-4A31-8E05-B2586DA86896

P2093

Q37685449-1DFE3BD7-50AF-490A-9D39-25B88FFFA800

Q37685449-8D14E075-83ED-41CA-8B99-9A19F02B6C80

Q37685449-AF795386-6B40-4D27-A1F8-00C7C97124A3

P2860

Q37685449-03344542-7A0B-4A40-A470-D92BADE5E9E9

Q37685449-0A64258A-644B-497B-AA37-B93563E85943

Q37685449-105993C5-027C-45A0-9CFB-86C6A4469EB4

Q37685449-14B1968A-1D9B-4ACB-9CFC-28B5933206BD

Q37685449-1612890D-7D60-4C0C-B9C3-6DFD73F79C93

Q37685449-19A101E5-5513-4EFC-977D-3AF790FD9366

Q37685449-1A71E0CD-34C4-4214-BA6E-56EDDF9384FA

Q37685449-22C710AE-D397-47ED-A9FE-9E411CFA1C85

Q37685449-26A5146B-0215-42FB-99BB-DBDB976D3928

Q37685449-286DE210-9B47-4D0D-ADA0-F331CCC628E5

P2888

Q37685449-89B6F362-E91A-482D-AE35-02CA48688E47

P304

Q37685449-122EF28D-0791-49D8-8835-31689BD2CFD3

P31

Q37685449-D32AB90D-4146-4DBB-9BA0-585577D318B6

P356

Q37685449-0FF3275C-CF6C-4DAA-A6C2-9B6E6BB3CDA8

P407

Q37685449-EC06C301-6109-4961-98AD-6C3211EADC69

P433

Q37685449-572BD55F-F468-4281-9CDD-733F167D42E9

P478

Q37685449-D4187ED1-43DA-485B-B311-72A05861CCA2

P50

Q37685449-734F40D8-C8F4-461B-B115-394808B08F80

Q37685449-7516A57C-0788-41A0-B3FD-238410C025D8

Q37685449-B64F8831-4B3D-4654-A0FF-E9B50705D94E

Q37685449-EA538268-747B-4578-95D1-2ED18284146E

Q37685449-F8114FDF-3937-4CB2-BD0C-5AF3D1AAC714

P577

Q37685449-AA0BDFA7-68F7-47BD-B845-53C75A34DF67

P6179

Q37685449-A672B88E-929F-4B0D-9A8E-30EA92477D41

P698

Q37685449-8E08F616-52B8-44B4-8959-A6C3D6567830

P932

Q37685449-63CE2FD3-A475-4619-B052-7BD79018449F

P356

P1433

P1476

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

@en

P2093

A Thuleau

http://www.w3.org/2001/XMLSchema#string

A Vincent-Salomon

http://www.w3.org/2001/XMLSchema#string

P Sirven

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular profiling of patient-derived breast cancer xenografts

Involvement of chemokine receptors in breast cancer metastasis

A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)

Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

P2888

P304

1211-1222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2016.284

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Fatima Mechta-Grigoriou

Elisabetta Marangoni

P577

2016-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050812094

http://www.w3.org/2001/XMLSchema#string

P698

27669438

http://www.w3.org/2001/XMLSchema#string

P932

5340801

http://www.w3.org/2001/XMLSchema#string